AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 OCT 10 - (NewsRx.com & NewsRx.net) -- by Sonia Nichols, senior medical writer - If doctors could just figure out a way of getting the therapy to its intended target, angiostatin gene therapy might provide a new means for treating women with endometriosis.
Angiostatin is a natural inhibitor of angiogenesis, or new vessel growth. Angiogenesis has been implicated in endometriosis, a disorder marked by endometrial tissue growth outside of the uterus. Angiostatin gene therapy could potentially spare thousands of women with endometriosis their infertility and debilitating pain associated with it. However, doctors must first devise a way to deliver the therapy only to intended tissues.
Murine model experiments conducted at MacMaster University in Hamilton, Ontario, Canada, have confirmed the utility of angiostatin for treating endometriosis. In those experiments, Charlotta Dabrosin and colleagues administered the gene therapy (AdAngiostatin) into the abdominal cavities of mice who's ovaries had been removed. The mice were given estrogen supplementation for hormonal control.
The therapy could be detected in the animals for up to 10 days after administration.
"Established endometriosis was eradicated in 14 of 14 AdAngiostatin-treated animals, whereas 11 of 13 control animals showed full disease development," Dabrosin and colleagues reported.
In animals in which ovaries had not been removed, ...
Source: HighBeam Research, Angiostatin gene transfer obliterates endometriosis in study...